TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-80 years~* Histologically confirmed (according to the WHO classification) diffuse large B-cell lymphoma stage II-IV~* No previous treatment for lymphoma. Corticosteroids for alleviation of lymphoma associated symptoms are allowed~* WHO performance status 0-2~* HIV negativity~* Seronegativity for HCV, HBsAg, anti-HBc, or other active infection uncontrolled by treatment~* Absence of psychiatric illness or condition which could interfere with the subjects ability understand the requirements of the study~* Absence of neurological or neuropsychiatric disorder, interfering with the requirements of the study~* Absence of hearing impairment \> grade 2~* Absence of porphyria~* In females: absence of pregnancy and lactation~* All subjects must agree to abstain from donating blood while taking study drug therapy and for one week following discontinuation of study drug therapy~* All subjects must agree not to share study medication with another person, and to return all unused study drug to investigators~* Written informed concent according to ICH/GCP and Swedish regulations

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Single, open labeld. (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed de novo GBM with documented EGFRvIII expression in tumor tissue.~* Gross total resection followed by conventional chemoradiation therapy without progression of disease.~Exclusion Criteria:~* Presence of diffuse leptomeningeal disease or gliomatosis cerebri.~* Systemic corticosteroid therapy \> 2 mg of dexamethasone or equivalent (as defined by the investigator) per day at study enrollment.~* Patients who have undergone stereotactic radiosurgery prior to or following surgical resection, or the placement of Gliadel® Wafers.~* Known allergy or hypersensitivity to KLH, GM-CSF or yeast derived products, or a history of anaphylactic reactions to shellfish proteins.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CDX-110 with GM-CSF (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Left Ventricular Dysfunction During Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients 18-70 years old~* Sinus rhythm~* Normal LVEF (\>=50%)~* Patients recently diagnosed of acute leukemia to be submitted to intensive chemotherapy or~* Patients with other hemopathies submitted to autologous peripheral blood stem cell transplantation~* Signed informed consent~Exclusion Criteria:~* Congestive heart failure~* LVEF\<50%~* Coronary artery disease,~* significant valvulopathy or myocardiopathy~* Renal failure (MDRD\<30)~* Liver failure~* Ongoing or expected need to be treated with angiotensin-converting enzyme inhibitors (ACE-i),angiotensin II receptor blockers (ARB) or beta-blockers~* Prior allergy to ACEI or ARB~* Systolic blood pressure \<90 mmHg~* Asthma~* Auriculoventricular (AV) block or sinus bradycardia (HR\<60 bpm)~* Persistent atrial fibrillation~* Need to be treated with Class I antiarrhythmic drugs~* Pregnancy~* Inability or unwillingness to give unformed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Enalapril and carvedilol (Type: EXPERIMENTAL): Enalapril 2.5 to 10 mg BID plus Carvedilol 6.25 to 25 mg BID
- Control (Type: NO_INTERVENTION): Control arm without intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study in Infants to Test Two Preparations (Freeze-dried or Liquid) of the Rotavirus Vaccine (HRV Vaccine).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy infants birth weigh \>2000 g, 11 -17 weeks old at Dose 1 with written informed consent.~Exclusion Criteria:~* Allergic reaction to vaccine components; clinically significant history of chronic GI disease (uncorrected GI congenital malformation) or other serious medical condition per investigator, received vaccines or treatment prohibited by the protocol; immunocompromised.

- Gender: ALL
- Minimum Age: 11 Weeks
- Maximum Age: 17 Weeks
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Omega-3 Fatty Acids on Aspirin Resistance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Willing to participate by providing informed consent and committing to complete the study. This includes adhering to the study diet.~* No chronic disease by history and based on a complete blood count and comprehensive metabolic profile.~* Commitment to not taking aspirin, non-steroidal anti-inflammatory medications, and to limit fish intake to ≤2 meals during the 7 days prior to each CRC study period. They will also need to abstain from taking a list of over-the-counter medications that include aspirin. For the duration of the study, they will also be asked to abstain from taking fish and flax seed oil supplements.~Exclusion Criteria:~* Reports the presence of chronic disease (e.g. cardiovascular, renal, hepatic, neurodegenerative, neoplastic, metabolic {diabetes}, hypertension).~* Reports taking a systemic medication chronically.~* History of serious adverse reaction or allergy to aspirin or fish oil.~* Baseline platelet count \<100 000 or \>500 000, hematocrit \<30%, or white blood cell count \>20 000.~* Any abnormality from a screening CBC and complete blood count that suggests acute or chronic disease.~* Nicotine user.~* History of alcohol abuse~* Pregnancy by history or urine/serum pregnancy test~* History of intestinal malabsorption syndrome including gastric bypass surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Placebo, Lovaza, Aspirin, Both Aspirin and Lovaza (Type: EXPERIMENTAL): First Placebo, then 4 grams of Lovaza, then 81mg of Aspirin, then both 4 grams of Lovaza and 81 mg of Aspirin
- Aspirin, Lovaza, Both Aspirin and Lovaza, Placebo (Type: EXPERIMENTAL): First 81mg of Aspirin, then 4 grams of Lovaza, then both 81mg of Aspirin and 4 grams of Lovaza, then placebo
- Lovaza, Both Aspirin and Lovaza, Placebo, Aspirin (Type: EXPERIMENTAL): First 4 grams of Lovaza, then both 81mg of Aspirin and 4 grams of Lovaza, then placebo, then 81mg of Aspirin
- Both Aspirin and Lovaza, Placebo, Lovaza, Aspirin (Type: EXPERIMENTAL): First both 81mg of Aspirin and 4 grams of Lovaza, then placebo, then 4 grams of Lovaza, then 81mg of Aspirin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Post-operative Dental Pain Study Comparing Two Different Dosage of Analgesic Efficacy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects aged 18 to 45 years with moderate-to-severe dental pain as assessed by verbal rating scale (VRS) and confirmed by a score of at least 50 mm out of 100 mm using a visual analogue (VAS) following the surgical removal of up to two mandibular third molars. If only one mandibular third molar is removed, it must be a full bony impaction. If two mandibular third molars are removed, both may be partial bony impactions OR there may be a combination of one full bony impaction with the second tooth being erupted, soft tissue impaction, or partial bony impaction. Ipsilateral maxillary third molars may be removed at the surgeon's discretion, regardless of impaction level.~Exclusion Criteria:~* Pregnant and lactating females~* Allergy/intolerance to study materials or nitrous oxide or local anaesthetic used during surgery~* Current or recurrent liver, kidney or cardiac disease, stomach ulcers, gastrointestinal bleeding, gastroesophageal reflux disease, bronchospasm, rhinitis, urticaria or asthma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Paracetamol 1000mg (Type: EXPERIMENTAL): Paracetamol 1000mg
- Paracetamol 650 mg (Type: EXPERIMENTAL): Paracetamol 650 mg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1/2a Clinical Trial to Assess the Safety of HB-adMSCs for the Treatment of Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male or female between the ages of 18 and 65~* Patients have active RA as confirmed by the following criteria:~  * ≥ 6 swollen joints and ≥ 6 tender joints at screening (68-joint count)~ * Abnormal CRP result OR abnormal ESR result at screening. Abnormal CRP result at screening OR abnormal ESR defined as:~ * CRP \> 4.9 mg/L or ESR \> 10mm/hr for men, \> 20mm/hr for women~* Patients without current established treatment, or if being treated, patients who are on a stable dose of RA therapy regimen for ≥ 4 weeks prior to screening~Exclusion Criteria:~* Inability to understand and provide signed informed consent~  * Pregnancy, lactation, or, if female of childbearing potential, positive serum β-hCG at screening.~ * Currently diagnosed any malignant neoplasm. Any patient who was successfully treated for cancer and has been disease-free, with no recurrence, for at least 5 years, will be considered.~ * Uncontrolled systemic illness, including, but not limited to: hypertension (systolic \>150 mm Hg or diastolic \>95 mm Hg); diabetes; renal, hepatic, or cardiac failure or any laboratory abnormality that poses a safety risk to the subject such as:~    * Hemoglobin ≤8.5 g/dL~   * White blood cells (WBCs) ≤3,500/mm3 (3.5 G/L)~   * Any other illness which, in the opinion of the investigator, characterizes the subject as not being a good candidate for the study~ * Participation in another study with an investigational drug or device within 4 weeks prior to treatment or 5 half-lives of the investigational product used (whichever is longer).~ * Positive results of hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb), hepatitis B core antibody (HBcAb), hepatitis C antibody (HCV Ab), and/or human immunodeficiency virus antibody (HIV Ab) tests at screening (excluding patients who are tested positive for HBsAb alone due to a hepatitis B vaccination).~ * Positive history of Treponema pallidum.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Single IV administration of autologous adipose-derived mesenchymal stem cells Baseline laboratory data will be collected prior to infusion; follow up data will be compared against baseline at 1, 3, 6 and 12 months. Joint Assessment 68 will be administered at 1, 3, 6 and 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Renal Transplant Recipients (MyLife)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Received kidney transplant at least 3 months prior to study enrollment~* Receiving immunosuppressive regimen that includes MMF in combination with other immunosuppressive drugs~* Receiving MMF for at least 1 month prior to enrollment~Exclusion Criteria:~* Patients with any known hypersensitivity against mycophenolic acid, mycophenolate sodium, mycophenolate mofetil or other components of the formulations (e.g. lactose; see also summary of product characteristics of EC-MPS)~* If applicable, GI symptoms assumed or known not to be caused by MPA therapy (e.g. oral biphosphonates induced, infectious diarrhea)~* Acute rejection \< 1 week prior to study enrollment~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Myfortic (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: High-Volume Plasma Exchange Versus Standard Medical Treatment in Patients With Acute Liver Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with acute liver failure defined as : Patients with jaundice which is complicated by encephalopathy and coagulopathy within 4 weeks of the onset of jaundice and without underlying chronic liver disease.~Exclusion Criteria:~* Age \<12 or \> 75 years~* Hepato-Cellular Carcinoma~* Active untreated Sepsis/DIC~* Any evidence of active bleed secondary to coagulopathy~* Hemodynamic instability requiring high dose of Vasopressors~* Coma of non-hepatic origin.~* Pregnancy~* Comorbidities associated with poor outcome (Extrahepatic neoplasia, severe cardiopulmonary disease defined by a New York Heart Association score \>3, or oxygen/steroid-dependent chronic obstructive pulmonary disease).~* Patients being taken up for liver transplant~* Refusal to participate in the study.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Standard medical therapy with Plasma Exchange (Type: EXPERIMENTAL): Plasma Exchange will be performed for consecutive days. Standard medical therapy included as per requirement,management of cerebral edema/intracranial hypertension: transfer to ICU,prophylactic antibiotics, intubation of trachea (as required),administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure,volume replacement and pressor support (norepinephrine, vasopressin) as needed, NAC, correction of metabolic parameters and nutrition.
- Standard medical therapy alone (Type: ACTIVE_COMPARATOR): Standard medical therapy included as per requirement,management of cerebral edema/intracranial hypertension: transfer to ICU,prophylactic antibiotics, intubation of trachea (as required),administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure,volume replacement and pressor support (norepinephrine, vasopressin) as needed, NAC, correction of metabolic parameters and nutrition.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Heterozygous for the F508del mutation (F/MF)~* Forced expiratory volume in 1 second (FEV1) value ≥40% and ≤90% of predicted mean for age, sex, and height~Key Exclusion Criteria:~* Clinically significant cirrhosis with or without portal hypertension~* Lung infection with organisms associated with a more rapid decline in pulmonary status~* Solid organ or hematological transplantation~Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants who received placebo matched to VX-445/TEZ/IVA for 24 weeks in the TC treatment period.
- VX-445/TEZ/IVA TC (Type: EXPERIMENTAL): Participants who received VX-445 200 mg/TEZ 100 mg/IVA150 mg as fixed-dose combination (FDC) tablets in the morning and IVA 150 mg as mono tablet in the evening for 24 weeks in the TC treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Have had type 2 diabetes (T2D) for ≥6 months according to the World Health Organization (WHO) classification~* Have HbA1c of 7.0% to 10.0%, inclusive, as assessed by the central laboratory~* Have been treated with stable doses of metformin for at least 3 months~* Have a body mass index (BMI) ≥25 kilograms per square meter~Exclusion Criteria:~* Have type 1 diabetes (T1D)~* Have used any glucose-lowering medication other than metformin 3 months prior to study entry or during screening/lead-in period or have used any glucagon-like peptide-1 receptor agonists (GLP-1 RAs) at any time in the past~* Have had any of the following cardiovascular conditions: acute myocardial infarction (MI), New York Heart Association Class III or Class IV heart failure, or cerebrovascular accident (stroke)~* Have acute or chronic hepatitis, signs and symptoms of any other liver disease other than nonalcoholic fatty liver disease (NAFLD), or alanine aminotransferase (ALT) level \>2.5 times the upper limit of the reference range, as determined by the central laboratory at study entry; participants with NAFLD are eligible for participation in this trial~* Have had chronic or acute pancreatitis any time prior to study entry~* Have an estimated glomerular filtration rate (eGFR) \<45 milliliters/minute/1.73 square meter, calculated by the Chronic Kidney Disease-Epidemiology (CKD-EPI) equation~* Have serum calcitonin ≥20 picograms per milliliter, as determined by the central laboratory at study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dulaglutide 4.5mg (Type: EXPERIMENTAL): 4.5mg of Dulaglutide administered subcutaneously (SC)
- Dulaglutide 3.0mg (Type: EXPERIMENTAL): 3.0mg of Dulaglutide administered SC
- Dulaglutide 1.5mg (Type: ACTIVE_COMPARATOR): 1.5mg of Dulaglutide administered SC
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered SC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine as Adjuvant for FNB in TKA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I-II~* scheduled for total knee arthroplasty~Exclusion Criteria:~* refusal to participate in this study~* unicompartmental knee arthroplasty~* BMI \> 35 kg/m2~* congnitive or phychiatric history~* refusal of general anesthesia~* contraindication to laryngeal mask airway insertion~* contraindication to peripheral nerve block (localized infections, sepsis, coagulopathy, bleeding diathesis or preexisting lower extremity neurological abnormality)~* allergy to the drugs used

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- H group (Type: EXPERIMENTAL): H group stands for High concentration group. A single bolous of 20 ml ropivacaine 0.2% in ultrasound-guided femoral nerve block (FNB) before the TKA surgery, followed by continuous femoral nerve block (CFNB) using ropivacaine 0.2% (5 ml/h) for postoperative analgesia which started right after surgery. After surgery, all patients received multimodal analgesia of 200mg celecoxib every 12 hours. All subjects received anothother intravenous patient-controlled analgesia pump (IV-PCA pump), which included 50 mg morphine in 50 ml saline: bolus 2 mg; lock out time, 15 minutes.
- L group (Type: EXPERIMENTAL): L group stands for low concentration group. A single bolous of 20 ml ropivacaine 0.1% in ultrasound-guided femoral nerve block (FNB) before the TKA surgery, followed by continuous femoral nerve block (CFNB) using ropivacaine 0.1% (5 ml/h) for postoperative analgesia which started right after surgery. All subjects received anothother intravenous patient-controlled analgesia pump (IV-PCA pump), which included 50 mg morphine in 50 ml saline: bolus 2 mg; lock out time, 15 minutes.
- LD group (Type: EXPERIMENTAL): LD group stands for low concentration group with dexmedetomidine. A single bolous of 20 ml ropivacaine 0.1% plus 2 μg/kg dexmedetomidine in ultrasound-guided femoral nerve block (FNB) before the TKA surgery, followed by continuous femoral nerve block (CFNB) using ropivacaine 0.1% (5 ml/h) for postoperative analgesia which started right after surgery. All subjects received anothother intravenous patient-controlled analgesia pump (IV-PCA pump), which included 50 mg morphine in 50 ml saline: bolus 2 mg; lock out time, 15 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete